|
?:authorAffiliation
|
-
[\'MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK; HIV Prevention Trials Network Modelling Centre, Imperial College London, London, UK; Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London, London, UK. Electronic address: kate.mitchell@imperial.ac.uk.\', \'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.\', \'MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK; HIV Prevention Trials Network Modelling Centre, Imperial College London, London, UK; Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London, London, UK.\', \'MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK; Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London, London, UK.\', \'Department of Medicine, University of California San Francisco, San Francisco, CA, USA; Bridge HIV, Population Health Division, San Francisco Department of Public Health, San Francisco, CA, USA.\', \'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.\', \'The Fenway Institute, Fenway Health, Boston, MA, USA; Harvard Medical School and TC School of Public Health, Boston, MA, USA.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}